Private-equity firm Veritas Capital Fund Management, L.L.C is close to a deal to sell a stake in Cotiviti, Inc. to alternative-asset manager KKR & Co. Inc. (NYSE:KKR) in a deal that would value the healthcare-technology company at around $11 billion. KKR could finalize an agreement to buy a 50% stake in Cotiviti from Veritas as soon as in the coming weeks, people familiar with the matter said, assuming the talks don?t fall apart.

Skadden, Arps, Slate, Meagher & Flom LLP has represented Veritas Capital and its portfolio company Cotiviti, Inc. in the sale of a stake in Cotiviti to KKR & Co. Inc.